Opening Asia for Russia

WHO approves emergency use of India's Covaxin vaccine

04.11.2021 132 просмотров

Covaxin is the eighth vaccine recommended by the organization for emergency use in the fight against the coronavirus pandemic.

The World Health Organization (WHO) on Wednesday approved the emergency use of India's coronavirus vaccine Covaxin. This is stated in a message distributed by the WHO.

"Today, the WHO issued a decision on the emergency use of the drug Covaxin, which joined the growing list of vaccines approved by WHO for the prevention of COVID-19," the text says. Studies have shown that the effectiveness of the drug for COVID-19 of any severity after 14 days or more after the introduction of the second dose was 78%. The WHO emphasizes that the vaccine, due to its simple storage conditions, is very well suited for low- and middle-income countries.

The organization's experts have allowed Covaxin to be given to all persons 18 years of age and older. The vaccine is recommended to be administered in two doses four weeks apart. WHO does not yet have sufficient data to assess the safety and efficacy of immunization with this drug in pregnant women, the organization is going to conduct additional studies.

Covaxin became the eighth vaccine recommended by WHO for emergency use in the fight against the coronavirus pandemic. More than ten other vaccines are in the process of being considered for approval, including the Russian Sputnik V and Epivaccorona.

The WHO decision will allow Covaxin to be accepted in most countries of the world. The approval of this vaccine, developed and produced in India, is waiting for many citizens of this country who are planning to travel abroad. According to the Ministry of Health, about 12% of the total number of Indians who were immunized were vaccinated with Covaxin.

Новости партнёров